U.S. Blood Transfusion Diagnostics Market Size, Trends, Growth, Opportunities | Grifols, S.A., F. Hoffmann-La Roche Ltd, and QuidelOrtho Corporation

The U.S. blood transfusion diagnostics market was valued at USD 1.91 billion in 2021 and is projected to grow from USD 2.20 billion in 2022 to USD 3.58 billion by 2029, recording a CAGR of 7.2% during the forecast period.

The U.S. Blood Transfusion Diagnostics Market is witnessing remarkable growth, driven by advancements in diagnostic technologies, increasing demand for safe blood transfusions, and stringent regulatory standards. The market focuses on ensuring safety and accuracy in blood grouping, screening, and compatibility testing, vital for patient outcomes in critical care scenarios.

𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿 𝗪𝗵𝗮𝘁 𝗬𝗼𝘂'𝗿𝗲 𝗠𝗶𝘀𝘀𝗶𝗻𝗴: 𝗚𝗲𝘁 𝗮 𝗙𝗿𝗲𝗲 𝗥𝗲𝗽𝗼𝗿𝘁 (𝗣𝗗𝗙) 𝗦𝗮𝗺𝗽𝗹𝗲: https://www.fortunebusinessinsights.com/enquiry/sample/u-s-blood-transfusion-diagnostics-market-107024

𝗞𝗲𝘆 𝗜𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁

In June 2022, Alba Bioscience Limited (QUOTIENT LIMITED) achieved a significant milestone by receiving USFDA approval for its ORTHO Sera and ALBAclone blood grouping reagents. This approval underscores the company's commitment to advancing transfusion diagnostics and ensuring reliable and accurate blood grouping solutions in the U.S.

𝗧𝗼𝗽 𝗖𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀 𝗶𝗻 𝘁𝗵𝗲 𝗨.𝗦. 𝗕𝗹𝗼𝗼𝗱 𝗧𝗿𝗮𝗻𝘀𝗳𝘂𝘀𝗶𝗼𝗻 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀 𝗠𝗮𝗿𝗸𝗲𝘁

• QUOTIENT LIMITED (Switzerland)
• Grifols, S.A. (Spain)
• Immucor, Inc. (U.S.)
• Bio-Rad Laboratories, Inc. (U.S.)
• Merck KGaA (Germany)
• Beckman Coulter, Inc. (Danaher) (U.S.)
• QuidelOrtho Corporation (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Abbott (U.S.)

𝗠𝗮𝗿𝗸𝗲𝘁 𝗗𝗿𝗶𝘃𝗲𝗿𝘀

𝗜𝗻𝗰𝗿𝗲𝗮𝘀𝗶𝗻𝗴 𝗗𝗲𝗺𝗮𝗻𝗱 𝗳𝗼𝗿 𝗦𝗮𝗳𝗲 𝗕𝗹𝗼𝗼𝗱 𝗧𝗿𝗮𝗻𝘀𝗳𝘂𝘀𝗶𝗼𝗻𝘀

The rising number of surgical procedures, trauma cases, and chronic diseases has amplified the need for safe and efficient blood transfusion diagnostics. Accurate blood screening and compatibility testing play a pivotal role in minimizing transfusion-related complications.

𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝗔𝗱𝘃𝗮𝗻𝗰𝗲𝗺𝗲𝗻𝘁𝘀 𝗶𝗻 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀

Innovations such as automated blood screening systems, next-generation sequencing, and AI-driven diagnostic tools are enhancing the precision and speed of blood transfusion processes, boosting market growth.

𝗦𝘁𝗿𝗶𝗻𝗴𝗲𝗻𝘁 𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗦𝘁𝗮𝗻𝗱𝗮𝗿𝗱𝘀

The U.S. government and healthcare agencies impose strict regulations on blood screening and transfusion practices, encouraging the adoption of advanced diagnostic technologies to meet compliance and safety standards.

𝗠𝗮𝗿𝗸𝗲𝘁 𝗥𝗲𝘀𝘁𝗿𝗮𝗶𝗻𝘁𝘀

𝗛𝗶𝗴𝗵 𝗖𝗼𝘀𝘁𝘀 𝗼𝗳 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰 𝗘𝗾𝘂𝗶𝗽𝗺𝗲𝗻𝘁

The significant investment required for advanced diagnostic equipment and reagents poses a challenge for smaller healthcare facilities, potentially limiting market penetration.

𝗦𝗵𝗼𝗿𝘁𝗮𝗴𝗲 𝗼𝗳 𝗦𝗸𝗶𝗹𝗹𝗲𝗱 𝗧𝗲𝗰𝗵𝗻𝗶𝗰𝗶𝗮𝗻𝘀

The lack of adequately trained professionals to operate sophisticated diagnostic tools and interpret results accurately remains a critical barrier to market growth.

𝗠𝗮𝗿𝗸𝗲𝘁 𝗥𝗲𝗽𝗼𝗿𝘁 𝗖𝗼𝘃𝗲𝗿𝗮𝗴𝗲

The market report provides an in-depth U.S. Blood Transfusion Diagnostics Market analysis, including a detailed assessment of key drivers, restraints, competitive landscape, regional insights, and segment performance. It also explores future growth opportunities and technological advancements shaping the industry.

𝗙𝗼𝗿 𝗙𝘂𝗹𝗹 𝗥𝗲𝗽𝗼𝗿𝘁 𝗖𝗼𝘃𝗲𝗿𝗮𝗴𝗲 𝗩𝗶𝘀𝗶𝘁: https://www.fortunebusinessinsights.com/u-s-blood-transfusion-diagnostics-market-107024

𝗠𝗮𝗿𝗸𝗲𝘁 𝗖𝗼𝗺𝗽𝗲𝘁𝗶𝘁𝗶𝘃𝗲 𝗟𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲

Leading players such as Grifols, Immucor, and Bio-Rad Laboratories are investing significantly in R&D and strategic collaborations to expand their market share. A focus on innovation, regulatory compliance, and cost-effectiveness drives the competition.

𝗠𝗮𝗿𝗸𝗲𝘁 𝗦𝗲𝗴𝗺𝗲𝗻𝘁𝘀

𝗕𝗹𝗼𝗼𝗱 𝗦𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴 𝗦𝗲𝗴𝗺𝗲𝗻𝘁 𝗟𝗲𝗮𝗱𝗶𝗻𝗴 𝘁𝗵𝗲 𝗠𝗮𝗿𝗸𝗲𝘁

The blood screening segment is expected to dominate the market during the forecast period, fueled by the increasing prevalence of infectious diseases and the need for accurate donor screening to prevent transfusion-transmitted infections (TTIs).

𝗖𝗼𝗺𝗽𝗮𝘁𝗶𝗯𝗶𝗹𝗶𝘁𝘆 𝗧𝗲𝘀𝘁𝗶𝗻𝗴 𝗦𝗲𝗴𝗺𝗲𝗻𝘁 𝗦𝗵𝗼𝘄𝗶𝗻𝗴 𝗦𝘁𝗿𝗼𝗻𝗴 𝗚𝗿𝗼𝘄𝘁𝗵

Compatibility testing, including crossmatching and antibody screening, is gaining traction due to its critical role in ensuring transfusion safety and reducing adverse reactions.

𝗠𝗮𝗿𝗸𝗲𝘁 𝗥𝗲𝗴𝗶𝗼𝗻𝗮𝗹 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀

The U.S. leads the global blood transfusion diagnostics market due to its robust healthcare infrastructure, advanced diagnostic technologies, and supportive government initiatives. Major metropolitan regions such as New York, Los Angeles, and Chicago drive demand, while rural areas present opportunities for market expansion with increased healthcare investments.

𝗙𝘂𝘁𝘂𝗿𝗲 𝗠𝗮𝗿𝗸𝗲𝘁 𝗦𝗰𝗼𝗽𝗲

• Development of portable and point-of-care blood transfusion diagnostic devices for faster and more accessible testing.
• Integration of AI and big data analytics to improve diagnostic accuracy and streamline transfusion workflows.
• Focus on cost-effective solutions to enhance market penetration in underserved regions.
• Advancements in molecular diagnostics for comprehensive and precise blood screening.

𝗖𝗼𝗻𝗰𝗹𝘂𝘀𝗶𝗼𝗻

The U.S. Blood Transfusion Diagnostics Market is poised for significant growth, driven by technological innovations, rising demand for safe transfusions, and supportive regulatory frameworks. With leading companies investing in cutting-edge solutions, the market is set to advance healthcare outcomes while addressing challenges related to cost and accessibility.

For more information, explore the U.S. Blood Transfusion Diagnostics Market Report.

𝗖𝘂𝘀𝘁𝗼𝗺𝗶𝘇𝗲 𝗧𝗵𝗶𝘀 𝗥𝗲𝗽𝗼𝗿𝘁 𝗔𝗰𝗰𝗼𝗿𝗱𝗶𝗻𝗴 𝗧𝗼 𝗬𝗼𝘂𝗿 𝗖𝗼𝗻𝘃𝗲𝗻𝗶𝗲𝗻𝗰𝗲: https://www.fortunebusinessinsights.com/enquiry/ask-for-customization/u-s-blood-transfusion-diagnostics-market-107024

𝗖𝗼𝗻𝘁𝗮𝗰𝘁 𝗨𝘀:
Fortune Business Insights™ Pvt. Ltd.
9th Floor, Icon Tower,
Baner, Pune-411045,
Maharashtra, India.
Phone:
U.S.:+1 833 909 2966 (Toll-Free)
U.K.: +44 808 502 0280 (Toll-Free)
APAC +91 744 740 1245
Email: sales@fortunebusinessinsights.com

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬:
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

This release was published on openPR.